Companies Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals (ADXS): executive pay, fiscal 2022
Free brief. Every figure links to the company’s own filing.
Ayala Pharmaceuticals, Inc. no longer files a proxy statement; its last pay data is FY2022.
CEO pay, last three years
- $625,398FY2021
- $703,768FY2022
CEO total pay was $703,768 in fiscal 2022, up from $625,398 in fiscal 2021.
FY2022: salary $643,427 · bonus $0 · stock awards $0 · option awards $0
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kenneth Berlin | $643,427 | $0 | $0 | $0 | $0 | $0 | $60,341 | $703,768 |
| President, Chief Executive Officer | ||||||||
| Andres Gutierrez | 494,944 | 0 | 0 | 0 | 0 | 0 | 38,683 | 533,627 |
| Senior VP, Chief Medical Officer | ||||||||
| Igor Gitelman | 299,985 | 0 | 0 | 0 | 0 | 0 | 42,224 | 342,209 |
| Interim Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| Kenneth Berlin | $703,768 | $625,398 | — | ↑ +78,370 |
| Andres Gutierrez | 533,627 | 472,032 | — | ↑ +61,595 |
| Igor Gitelman | 342,209 | 313,645 | — | ↑ +28,564 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's executive compensation programs are designed to retain and incentivize high-quality executives whose efforts are key to long-term success, rewarding them based on individual and corporate performance measured against established corporate and strategic goals. The Compensation Committee seeks to ensure that total compensation is fair, reasonable, and competitive while aligning executive compensation structure with stockholders' interests and current market practices.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2022
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Igor Gitelman | Option | 208 | 31.2 | — |
| Kenneth Berlin | Option | 208 | 52.8 | — |
| Andres Gutierrez | Option | 208 | 52.8 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David SidranskyIndependent · Compensation · Nominating and Corporate Governance · Research and Development | $105,000 | — | $0 | — | — | $105,000 |
| James PattonIndependent · Nominating and Corporate Governance | 87,500 | — | 0 | — | — | 87,500 |
| Richard J. BermanIndependent · Nominating and Corporate Governance | 72,500 | — | 0 | — | — | 72,500 |
| Samir N. KhleifIndependent · Nominating and Corporate Governance · Research and Development | 67,500 | — | 0 | — | — | 67,500 |
| Roni A. AppelIndependent · Compensation · Audit · Research and Development · Nominating and Corporate Governance | 62,500 | — | 0 | — | — | 62,500 |
| Vered Bisker-LeibIndependent · Compensation · Audit · Newly elected | 0 | — | 0 | — | — | 0 |
| Igor GitelmanEmployee director | — | — | — | — | — | 0 |
| Robert SpiegelIndependent · Nominating and Corporate Governance · Research and Development · Newly elected | 0 | — | 0 | — | — | 0 |
| Murray A. GoldbergIndependent · Audit · Newly elected | 0 | — | 0 | — | — | 0 |
| Kenneth BerlinEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $395,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $395,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Ayala Pharmaceuticals as a peer
Companies that benchmark against ADXS
No companies currently name ADXS as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Ayala Pharmaceuticals, Inc. | 2022 | Kenneth Berlin | $643,427 | $0 | $0 | $0 | $703,768 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (16 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Kenneth Berlin. DEF 14A, filed 2023-06-23. Section “Executive Compensation”. As printed: 703,768. View filing ↗
- Section 01, Andres Gutierrez. DEF 14A, filed 2023-06-23. Section “Executive Compensation”. As printed: 533,627. View filing ↗
- Section 01, Igor Gitelman. DEF 14A, filed 2023-06-23. Section “Executive Compensation”. As printed: 342,209. View filing ↗
- Section 08, David Sidransky. DEF 14A, filed 2023-06-23. Section “Director Compensation”. As printed: 105,000. View filing ↗
- Section 08, James Patton. DEF 14A, filed 2023-06-23. Section “Director Compensation”. As printed: 87,500. View filing ↗
- Section 08, Richard J. Berman. DEF 14A, filed 2023-06-23. Section “Director Compensation”. As printed: 72,500. View filing ↗
- Section 08, Samir N. Khleif. DEF 14A, filed 2023-06-23. Section “Director Compensation”. As printed: 67,500. View filing ↗
- Section 08, Roni A. Appel. DEF 14A, filed 2023-06-23. Section “Director Compensation”. As printed: 62,500. View filing ↗
- Section 08, Vered Bisker-Leib. DEF 14A, filed 2023-06-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Igor Gitelman. DEF 14A, filed 2023-06-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Robert Spiegel. DEF 14A, filed 2023-06-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Murray A. Goldberg. DEF 14A, filed 2023-06-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Kenneth Berlin. DEF 14A, filed 2023-06-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 395,000 + equity 0 + all other 0 = 395,000, summed across the director compensation table rows.
- Ayala Pharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2023-06-23. CEO total compensation as printed in Ayala Pharmaceuticals, Inc.'s own proxy. As printed: 703,768. View filing ↗